Artículos por temáticas

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

Ittner LM, Götz J.

Nat Rev Neurosci. 2011 Feb;12(2):65-72. doi: 10.1038/nrn2967. Epub 2010 Dec 31.

Pathological significance of ganglioside clusters in Alzheimer's disease

Yanagisawa K.

J Neurochem. 2011 Mar;116(5):806-12. doi: 10.1111/j.1471-4159.2010.07006.x. Epub 2011 Jan 7.

Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology

Xiong L, Xuereb JH, Spillantini MG, Patterson K, Hodges JR, Nestor PJ.

J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):254-60. doi: 10.1136/jnnp.2010.209916. Epub 2010 Sep 14.

The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: a meta-analysis

Zhang Y, Zhang J, Tian C, Xiao Y, Li X, He C, Huang J, Fan H.

J Neurol Sci. 2011 Apr 15;303(1-2):133-8. doi: 10.1016/j.jns.2010.12.005. Epub 2011 Jan 20.

Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's disease

Texel SJ, Mattson MP.

Antioxid Redox Signal. 2011 Apr 15;14(8):1519-34. doi: 10.1089/ars.2010.3569. Epub 2011 Feb 17.

Regions of homozygosity and their impact on complex diseases and traits

Ku CS, Naidoo N, Teo SM, Pawitan Y.

Hum Genet. 2011 Jan;129(1):1-15. doi: 10.1007/s00439-010-0920-6. Epub 2010 Nov 23.

Age-related macular degeneration (AMD): Alzheimer's disease in the eye?

Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M.

J Alzheimers Dis. 2011;24(4):615-31. doi: 10.3233/JAD-2011-101908.

BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease

Venturelli E, Villa C, Fenoglio C, Clerici F, Marcone A, Benussi L, Ghidoni R, Gallone S, Cortini F, Serpente M, Cantoni C, Fumagalli G, Ridolfi E, Cappa S, Binetti G, Franceschi M, Rainero I, Giordan

J Alzheimers Dis. 2011;23(4):701-7. doi: 10.3233/JAD-2010-101416.

Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo

Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Långström B, Nordberg A.

Neurobiol Aging. 2011 Dec;32(12):2320.e15-32. doi: 10.1016/j.neurobiolaging.2010.04.028. Epub 2010 Jun 9.

Alzheimer's disease and intelligence

Yeo RA, Arden R, Jung RE.

Curr Alzheimer Res. 2011 Jun;8(4):345-53. doi: 10.2174/156720511795745276.

Unresolved questions concerning etiology of Alzheimer's disease: hypometabolism

Pluta R.

Nutrition. 2011 Jan;27(1):1-2. doi: 10.1016/j.nut.2010.07.010. Epub 2010 Sep 24.

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study

Frölich L, Ashwood T, Nilsson J, Eckerwall G; Sirocco Investigators.

J Alzheimers Dis. 2011;24(2):363-74. doi: 10.3233/JAD-2011-101554.

The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease

Jeynes B, Provias J.

J Neurosci Res. 2011 Jan;89(1):22-8. doi: 10.1002/jnr.22527.

[Alzheimer's disease and anaesthesia: potential relationships and clinical implications]

André D, Dartigues JF, Sztark F.

Ann Fr Anesth Reanim. 2011 Jan;30(1):37-46. doi: 10.1016/j.annfar.2010.10.013. Epub 2010 Nov 30.

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

Sabbagh M, Cummings J.

BMC Neurol. 2011 Feb 7;11:21. doi: 10.1186/1471-2377-11-21.